The 3rd Oligonucleotides for CNS Summit is the only industry event dedicated to the development of oligonucleotide therapeutics for neurological disorders. Our curated faculty and audience bring together expertise from pharma and biotech seeking to push the scientific and commercial opportunities in this exciting field.
Network with leaders in oligonucleotide chemistry, neurobiology, genomic targeting, and formulation from giants of Biogen, Genentech, Eli Lilly, Ionis, and Servier, as well as executives from pioneering biotechs such as QurAlis, Q-State Biosciences, and Praxis.
CNS Pharma and Biotech Companies Seek:
Cerebral organoids and iPSC-derived neurons for accurate neurodegenerative & neurodevelopmental disease modeling and candidate screening in RNAi and ASO therapeutics
Efficient manufacturing of compounds with expertise to enable custom, cost-effective synthesis, and scaling of process
NHP and rodent translational models to effectively assess oligonucleotide toxicity and distribution
Accurate analytics to precisely determine impurities and structure of oligonucleotides
Novel delivery methods of drug molecules – from transport vehicles through the BBB to advanced intrathecal pumps for effective spread of drug product throughout the CNS
Who Will You Meet?
If you provide any of the above or other products or services that could support biotech and pharma advancing Oligos for CNS, the 3rd Annual Oligonucleotides For CNS Summit will build a bespoke partnership package for you to showcase your expertise to this niche audience of high seniority decision makers at the helm of transforming neuroscience drug development.